AnaptysBio (ANAB) has disclosed a new risk, in the Regulation category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AnaptysBio faces a significant business risk as outlined in the risk factor titled ‘3333Item’. This risk could potentially impact their operational efficiency and financial stability. External analysts suggest that the company may need to implement strategic measures to mitigate this risk effectively. Failure to address this issue could result in adverse effects on their market position and investor confidence.
The average ANAB stock price target is $54.50, implying 122.00% upside potential.
To learn more about AnaptysBio’s risk factors, click here.